logo

Novavax Inc. (NVAX)



Trade NVAX now with
  Date
  Headline
9/25/2018 7:00:49 AM Novavax Begins Phase 2 Dose And Formulation Confirmation Clinical Trial In Older Adults Of NanoFlu
8/8/2018 4:09:21 PM Novavax Q2 Loss/share $0.12 Vs. Loss $0.16 Year Ago
5/9/2018 4:09:22 PM Novavax Q1 Loss/share $0.14 Vs. Loss $0.16 Year Ago
5/7/2018 7:02:03 AM Novavax Reports Significant Enrollment Milestone In Prepare Phase 3 Trial Of Its RSV F Vaccine
4/16/2018 4:13:24 PM Novavax Announces Closing Of Public Offering
4/11/2018 9:01:32 PM Novavax Prices Public Offering Of 30.30 Mln Shares At $1.65/shr For Gross Proceeds Of $50 Mln
4/11/2018 4:18:30 PM Novavax Announces Proposed Public Offering Of Common Stock
3/14/2018 4:10:58 PM Novavax Q4 Loss/share $0.16 Vs. Loss $0.21 Year Ago
3/14/2018 4:10:08 PM Novavax Promotes John Trizzino To Chief Business Officer And CFO
2/28/2018 4:14:12 PM Novavax Announces Positive Top-line Results From Phase 1/2 Clinical Trial Of Its NanoFlu Recombinant Influenza Vaccine